GMA 105
Alternative Names: GMA-105Latest Information Update: 26 Dec 2022
At a glance
- Originator Gmax Biopharm
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 26 Dec 2022 Phase II development for Obesity is still ongoing in Australia and New Zealand (Gmax Biopharma pipeline, December 2022)
- 26 Dec 2022 No development reported - Phase-III for Obesity in China (Parenteral) (Gmax Biopharm pipeline, December 2022)
- 29 Nov 2022 Phase III development for Obesity is still ongoing in China (Gmax Biopharma pipeline, November 2022)